.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,475,491

« Back to Dashboard

Summary for Patent: 6,475,491

Title: Treatment of HIV and other viral infections using combinatorial therapy
Abstract:Novel antiviral combinations for the treatment or prevention of viral infections, in particular, HIV, are disclosed. This new antiviral therapy employs either DP-178 or DP-107, viral fusion inhibitors, in combination with at least one other antiviral therapeutic agent. The combinations of the invention are better than single therapies alone, and in certain cases are synergistic. The use of DP-178 or DP-107 is an ideal therapy to combine with another antiviral, given both the novel mechanism which this therapeutic blocks HIV transmission and the non-toxicity of the therapeutic.
Inventor(s): Johnson; M. Ross (Chapel Hill, NC), Lambert; Dennis Michael (Cary, NC)
Assignee: Trimeris, Inc. (Durham, NC)
Application Number:08/973,952
Patent Claim Types:
see list of patent claims
Use; Dosage form; Composition;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 9th percentile
Forward Citations: 0th percentile

No matches for this query

Foreign Priority and PCT Information for Patent: 6,475,491

PCT Information
PCT FiledJune 06, 1996PCT Application Number:PCT/US96/09499
PCT Publication Date:December 19, 1996PCT Publication Number: WO96/40191

International Patent Family for Patent: 6,475,491

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia6261996► subscribe
Australia723537► subscribe
Brazil9609152► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc